Los Angeles Capital Management LLC Reduces Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Los Angeles Capital Management LLC lessened its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDXFree Report) by 8.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,738 shares of the biopharmaceutical company’s stock after selling 633 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Celldex Therapeutics were worth $229,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Celldex Therapeutics in the second quarter worth $76,000. CANADA LIFE ASSURANCE Co raised its stake in Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 955 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 1,582 shares during the last quarter. Quest Partners LLC boosted its position in Celldex Therapeutics by 1,364.9% during the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 6,879 shares during the period. Finally, Public Employees Retirement Association of Colorado purchased a new position in shares of Celldex Therapeutics in the first quarter worth about $327,000.

Celldex Therapeutics Stock Down 1.0 %

NASDAQ:CLDX opened at $23.31 on Tuesday. The stock has a market cap of $1.55 billion, a P/E ratio of -9.07 and a beta of 1.60. The business’s 50-day moving average price is $31.89 and its two-hundred day moving average price is $35.39. Celldex Therapeutics, Inc. has a twelve month low of $22.93 and a twelve month high of $53.18.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, November 7th. Citigroup initiated coverage on Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 price objective on the stock. Wolfe Research downgraded Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Finally, The Goldman Sachs Group began coverage on Celldex Therapeutics in a research report on Monday, September 30th. They set a “neutral” rating and a $45.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $62.25.

Read Our Latest Report on CLDX

Insider Buying and Selling at Celldex Therapeutics

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the stock in a transaction on Monday, November 11th. The shares were acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 3.80% of the stock is currently owned by company insiders.

About Celldex Therapeutics

(Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Featured Articles

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.